Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas

Abstract Background The GMZ2.6c malaria vaccine candidate is a multi-stage Plasmodium falciparum chimeric protein which contains a fragment of the sexual-stage Pfs48/45-6C protein genetically fused to GMZ2, a fusion protein of GLURP and MSP-3, that has been shown to be well tolerated, safe and immun...

Full description

Bibliographic Details
Published in:Malaria Journal
Main Authors: Barbara Oliveira Baptista, Ana Beatriz Lopes de Souza, Evelyn Kety Pratt Riccio, Cesare Bianco-Junior, Paulo Renato Rivas Totino, João Hermínio Martins da Silva, Michael Theisen, Susheel Kumar Singh, Linda Eva Amoah, Marcelo Ribeiro-Alves, Rodrigo Medeiros Souza, Josué Costa Lima-Junior, Cláudio Tadeu Daniel-Ribeiro, Lilian Rose Pratt-Riccio
Format: Article in Journal/Newspaper
Language:English
Published: BMC 2022
Subjects:
Online Access:https://doi.org/10.1186/s12936-021-04020-6
https://doaj.org/article/1c53bedbb908417a9a9a4057adf02661
id ftdoajarticles:oai:doaj.org/article:1c53bedbb908417a9a9a4057adf02661
record_format openpolar
spelling ftdoajarticles:oai:doaj.org/article:1c53bedbb908417a9a9a4057adf02661 2023-05-15T15:18:13+02:00 Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas Barbara Oliveira Baptista Ana Beatriz Lopes de Souza Evelyn Kety Pratt Riccio Cesare Bianco-Junior Paulo Renato Rivas Totino João Hermínio Martins da Silva Michael Theisen Susheel Kumar Singh Linda Eva Amoah Marcelo Ribeiro-Alves Rodrigo Medeiros Souza Josué Costa Lima-Junior Cláudio Tadeu Daniel-Ribeiro Lilian Rose Pratt-Riccio 2022-01-01T00:00:00Z https://doi.org/10.1186/s12936-021-04020-6 https://doaj.org/article/1c53bedbb908417a9a9a4057adf02661 EN eng BMC https://doi.org/10.1186/s12936-021-04020-6 https://doaj.org/toc/1475-2875 doi:10.1186/s12936-021-04020-6 1475-2875 https://doaj.org/article/1c53bedbb908417a9a9a4057adf02661 Malaria Journal, Vol 21, Iss 1, Pp 1-16 (2022) Malaria Plasmodium falciparum Immune response Antibodies GMZ2.6c Vaccine Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 article 2022 ftdoajarticles https://doi.org/10.1186/s12936-021-04020-6 2022-12-31T08:06:34Z Abstract Background The GMZ2.6c malaria vaccine candidate is a multi-stage Plasmodium falciparum chimeric protein which contains a fragment of the sexual-stage Pfs48/45-6C protein genetically fused to GMZ2, a fusion protein of GLURP and MSP-3, that has been shown to be well tolerated, safe and immunogenic in clinical trials performed in a malaria-endemic area of Africa. However, there is no data available on the antigenicity or immunogenicity of GMZ2.6c in humans. Considering that circulating parasites can be genetically distinct in different malaria-endemic areas and that host genetic factors can influence the immune response to vaccine antigens, it is important to verify the antigenicity, immunogenicity and the possibility of associated protection in individuals living in malaria-endemic areas with different epidemiological scenarios. Herein, the profile of antibody response against GMZ2.6c and its components (MSP-3, GLURP and Pfs48/45) in residents of the Brazilian Amazon naturally exposed to malaria, in areas with different levels of transmission, was evaluated. Methods This study was performed using serum samples from 352 individuals from Cruzeiro do Sul and Mâncio Lima, in the state of Acre, and Guajará, in the state of Amazonas. Specific IgG, IgM, IgA and IgE antibodies and IgG subclasses were detected by Enzyme-Linked Immunosorbent Assay. Results The results showed that GMZ2.6c protein was widely recognized by naturally acquired antibodies from individuals of the Brazilian endemic areas with different levels of transmission. The higher prevalence of individuals with antibodies against GMZ2.6c when compared to its individual components may suggest an additive effect of GLURP, MSP-3, and Pfs48/45 when inserted in a same construct. Furthermore, naturally malaria-exposed individuals predominantly had IgG1 and IgG3 cytophilic anti-GMZ2.6c antibodies, an important fact considering that the acquisition of anti-malaria protective immunity results from a delicate balance between cytophilic/non-cytophilic ... Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic Malaria Journal 21 1
institution Open Polar
collection Directory of Open Access Journals: DOAJ Articles
op_collection_id ftdoajarticles
language English
topic Malaria
Plasmodium falciparum
Immune response
Antibodies
GMZ2.6c
Vaccine
Arctic medicine. Tropical medicine
RC955-962
Infectious and parasitic diseases
RC109-216
spellingShingle Malaria
Plasmodium falciparum
Immune response
Antibodies
GMZ2.6c
Vaccine
Arctic medicine. Tropical medicine
RC955-962
Infectious and parasitic diseases
RC109-216
Barbara Oliveira Baptista
Ana Beatriz Lopes de Souza
Evelyn Kety Pratt Riccio
Cesare Bianco-Junior
Paulo Renato Rivas Totino
João Hermínio Martins da Silva
Michael Theisen
Susheel Kumar Singh
Linda Eva Amoah
Marcelo Ribeiro-Alves
Rodrigo Medeiros Souza
Josué Costa Lima-Junior
Cláudio Tadeu Daniel-Ribeiro
Lilian Rose Pratt-Riccio
Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas
topic_facet Malaria
Plasmodium falciparum
Immune response
Antibodies
GMZ2.6c
Vaccine
Arctic medicine. Tropical medicine
RC955-962
Infectious and parasitic diseases
RC109-216
description Abstract Background The GMZ2.6c malaria vaccine candidate is a multi-stage Plasmodium falciparum chimeric protein which contains a fragment of the sexual-stage Pfs48/45-6C protein genetically fused to GMZ2, a fusion protein of GLURP and MSP-3, that has been shown to be well tolerated, safe and immunogenic in clinical trials performed in a malaria-endemic area of Africa. However, there is no data available on the antigenicity or immunogenicity of GMZ2.6c in humans. Considering that circulating parasites can be genetically distinct in different malaria-endemic areas and that host genetic factors can influence the immune response to vaccine antigens, it is important to verify the antigenicity, immunogenicity and the possibility of associated protection in individuals living in malaria-endemic areas with different epidemiological scenarios. Herein, the profile of antibody response against GMZ2.6c and its components (MSP-3, GLURP and Pfs48/45) in residents of the Brazilian Amazon naturally exposed to malaria, in areas with different levels of transmission, was evaluated. Methods This study was performed using serum samples from 352 individuals from Cruzeiro do Sul and Mâncio Lima, in the state of Acre, and Guajará, in the state of Amazonas. Specific IgG, IgM, IgA and IgE antibodies and IgG subclasses were detected by Enzyme-Linked Immunosorbent Assay. Results The results showed that GMZ2.6c protein was widely recognized by naturally acquired antibodies from individuals of the Brazilian endemic areas with different levels of transmission. The higher prevalence of individuals with antibodies against GMZ2.6c when compared to its individual components may suggest an additive effect of GLURP, MSP-3, and Pfs48/45 when inserted in a same construct. Furthermore, naturally malaria-exposed individuals predominantly had IgG1 and IgG3 cytophilic anti-GMZ2.6c antibodies, an important fact considering that the acquisition of anti-malaria protective immunity results from a delicate balance between cytophilic/non-cytophilic ...
format Article in Journal/Newspaper
author Barbara Oliveira Baptista
Ana Beatriz Lopes de Souza
Evelyn Kety Pratt Riccio
Cesare Bianco-Junior
Paulo Renato Rivas Totino
João Hermínio Martins da Silva
Michael Theisen
Susheel Kumar Singh
Linda Eva Amoah
Marcelo Ribeiro-Alves
Rodrigo Medeiros Souza
Josué Costa Lima-Junior
Cláudio Tadeu Daniel-Ribeiro
Lilian Rose Pratt-Riccio
author_facet Barbara Oliveira Baptista
Ana Beatriz Lopes de Souza
Evelyn Kety Pratt Riccio
Cesare Bianco-Junior
Paulo Renato Rivas Totino
João Hermínio Martins da Silva
Michael Theisen
Susheel Kumar Singh
Linda Eva Amoah
Marcelo Ribeiro-Alves
Rodrigo Medeiros Souza
Josué Costa Lima-Junior
Cláudio Tadeu Daniel-Ribeiro
Lilian Rose Pratt-Riccio
author_sort Barbara Oliveira Baptista
title Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas
title_short Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas
title_full Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas
title_fullStr Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas
title_full_unstemmed Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas
title_sort naturally acquired antibody response to a plasmodium falciparum chimeric vaccine candidate gmz2.6c and its components (msp-3, glurp, and pfs48/45) in individuals living in brazilian malaria-endemic areas
publisher BMC
publishDate 2022
url https://doi.org/10.1186/s12936-021-04020-6
https://doaj.org/article/1c53bedbb908417a9a9a4057adf02661
geographic Arctic
geographic_facet Arctic
genre Arctic
genre_facet Arctic
op_source Malaria Journal, Vol 21, Iss 1, Pp 1-16 (2022)
op_relation https://doi.org/10.1186/s12936-021-04020-6
https://doaj.org/toc/1475-2875
doi:10.1186/s12936-021-04020-6
1475-2875
https://doaj.org/article/1c53bedbb908417a9a9a4057adf02661
op_doi https://doi.org/10.1186/s12936-021-04020-6
container_title Malaria Journal
container_volume 21
container_issue 1
_version_ 1766348434645712896